Home>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Ochromycinone

Ochromycinone

Catalog No.GC61627

Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

Ochromycinone Chemical Structure

Cas No.: 111540-00-2

Size Price Stock Qty
10mM (in 1mL DMSO)
$408.00
In stock
5 mg
$371.00
In stock
10 mg
$630.00
In stock
25 mg
$1,251.00
In stock
50 mg
$2,039.00
In stock
100 mg
$3,152.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity[1][2].

STA-21 inhibits STAT3 DNA binding activity, STAT3 dimerization, and STAT3-dependent luciferase activity. Moreover, STA-21 reduces the survival of breast carcinoma cells with constitutive STAT3 signaling but has minimal effect on the cells in which constitutive STAT3 signaling is absent[2].

[1]. Song H, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5. [2]. Nataliya I. Kalinovskaya, et al. New Angucyclinones from the Marine Mollusk Associated Actinomycete Saccharothrix espanaensis An 113. Natural product communications. 2008, 3(10):1611-1616.

Reviews

Review for Ochromycinone

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ochromycinone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.